Add Row 
Add 
A Game-Changer for Parkinson's Patients
Imagine only needing one shot each week to manage the challenges of Parkinson's disease instead of juggling multiple daily pills. Researchers at the University of South Australia have made this possible with a new long-acting levodopa gel designed to deliver consistent medication levels over seven days.
The Burden of Daily Doses
Parkinson's disease, affecting over 8.5 million people globally, brings tremors and rigidity, often requiring frequent medication to ease these symptoms. Patients, particularly the elderly or those who struggle with swallowing, find this regimen burdensome. This can lead to inconsistent drug levels, increased side effects, and reduced effectiveness of the treatment.
A Promising Development
The newly developed injectable formulation involves a biodegradable gel that releases levodopa and carbidopa – two essential medications for managing Parkinson's symptoms – at a steady rate. This offers a simpler approach, potentially enhancing patient compliance and overall treatment success. As Professor Sanjay Garg from UniSA's Centre for Pharmaceutical Innovation notes, simplifying treatment aims to keep medication levels consistent, drastically improving patient quality of life.
The Research Behind the Innovation
This revolutionary gel combines the FDA-approved polymer PLGA with Eudragit L-100, ensuring controlled drug release while maintaining safety and effectiveness. Initial lab tests showed promising results, highlighting over 90% of effective drug delivery. Furthermore, this innovation has already been filed for an Australian patent, signaling a bright future for involved researchers like UniSA PhD candidate Deepa Nakmode.
The Future of Parkinson's Care
This advancement not only brings hope to many battling Parkinson's but also signifies a potential shift in how neurological disorders are managed. With the promise of fewer pills and more straightforward treatment routines, this could indeed transform the landscape of Parkinson’s care.
Write A Comment